CanadianBiosimilars

Canadian Biosimilars Forum - Forum canadien des biosimilaires. Working to increase awareness, access and adoption of #biosimilars across Canada. RT≠endorsement

[CanadianBiosimilars @CanBiosimilars]

A recent study highlights the comparable efficacy and safety of an adalimumab biosimilar and its reference product!

We look forward to further research demonstrating the quality, safety, tolerability, and effectiveness of approved biosimilars.

https://t.co/EJVv8OTqpG

[CanadianBiosimilars @CanBiosimilars]

We applaud Ontario for its ongoing efforts to improve access to biosimilars!

As of July 31, 2024, Ontario’s Biosimilar Policy includes biosimilar versions of the following 4 originator biologics: Lucentis, Stelara, Lovenox, and Neupogen.

https://t.co/wLBUKhNP38

[CanadianBiosimilars @CanBiosimilars]

The Canadian Biosimilars Forum congratulates Manitoba on the launch of its Biosimilars Initiative, effective August 1, 2024! This marks an important step forward in improving pan-Canadian access to biosimilars.

https://t.co/gUSfolRsLn

[CanadianBiosimilars @CanBiosimilars]

An Environmental Scan on National and International Policies on the Use of Biosimilars was published today in the Canadian Journal of Health Technologies.

Access the full Environmental Scan here: https://t.co/tVlyDmTXI7

[CanadianBiosimilars @CanBiosimilars]

The Forum congratulates @BCGovNews for its ongoing leadership in Canadian policy by expanding access to biosimilars and reinvesting cost savings into BC PharmaCare to further improve drug coverage.

https://t.co/eqzdDvLcUL

[CanadianBiosimilars @CanBiosimilars]

Access the publication here: https://t.co/kxgIR2FLFO

[CanadianBiosimilars @CanBiosimilars]

@JCanAssnGastro recently published "An Update on Anti-TNF Biosimilar Switching — Real-World Clinical Effectiveness and Safety", which suggests that – in real-world practice – infliximab and adalimumab are as clinically effective as their respective originators for treating IBD.

[CanadianBiosimilars @CanBiosimilars]

Source: https://t.co/18u9XGiQfp

[CanadianBiosimilars @CanBiosimilars]

We applaud the European Medicines Agency’s proposal to waive clinical comparative efficacy studies for biosimilars that have straightforward mechanisms of action (e.g., monoclonal antibodies, recombinant proteins) – this could help to foster a more competitive biosimilars market.

[CanadianBiosimilars @CanBiosimilars]

Access the publication here: https://t.co/KXOQGhnu7A

[CanadianBiosimilars @CanBiosimilars]

Excited to share one of the largest real-world data reviews demonstrating long-term biosimilars safety: “Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch”.

[CanadianBiosimilars @CanBiosimilars]

To read the full coverage, please click here: https://t.co/d4JdAEd79g

[CanadianBiosimilars @CanBiosimilars]

Great news! Coverage of our presentation on “Biosimilars in Canada: Shifting from Why to How” at @BenCanMag’s Face to Face Drug Plan Management Forum has been released! In 2024, the Forum will continue to work with private payers to educate on the benefits of biosimilars.

[CanadianBiosimilars @CanBiosimilars]

Access the report here: https://t.co/JrIDXK8lCE

[CanadianBiosimilars @CanBiosimilars]

IQVIA’s report on “Assessing the Biosimilar Void” indicated that EU health systems may lose €15 billion in cost savings due to insufficient biosimilars competition. This highlights the importance of creating a competitive biosimilars market, a path that the Forum fully supports.

[CanadianBiosimilars @CanBiosimilars]

We are thrilled to announce that we recently presented at @BenCanMag's Face to Face Drug Plan Management Forum!

Our session on “Biosimilars in Canada: Shifting from Why to How” was presented alongside Neda Nasseri, Pharmacist, & Product Director for Drug Benefits at Desjardins.

[Benefits Canada @BenCanMag]

Last chance to register for the 2023 Face to Face Drug Plan Management Forum! Registration closes at 5 PM ET today, don’t miss your chance to learn valuable information on key drug plan topics! Register:
https://t.co/neTcLn4FRD

[Biosimilars Canada | Biosimilaires Canada @CDNBiosimilars]

Grâce aux médicaments génériques et biosimilaires, la RAMQ limite ses hausses de frais aux patients pour la prochaine année : https://t.co/1eNqAcMdv4

#biosimilaire #biosimilaires #biologiques #médicaments #patients #santé #soins #cdnpoli

[Biosimilars Canada | Biosimilaires Canada @CDNBiosimilars]

Thanks to generic and biosimilar medicines, RAMQ is limiting its rate increase to patients for the coming year: https://t.co/1eNqAcMdv4

#biosimilar #biosimilars #biologics #medicines #education #patients #health #healthcare #cdnpoli

[CenterForBiosimilars @BiosimCenter]

An analysis of 25 studies found adalimumab, infliximab, and etanercept #biosimilars were considered just as safe, effective, and tolerable compared with their originators in the treatment of rheumatoid arthritis. https://t.co/sRQK2DIOdT

[CanadianBiosimilars @CanBiosimilars]

Check out this Act4Biosimilars Deep Dive Report, outlining the key factors impacting #biosimilar adoption in countries across the Americas across Approvability, Acceptability, Accessibility and Affordability. https://t.co/DGEsFrOW54